BioSpace News Archive

Policy

Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine

Mylan N.V. and Biocon Ltd. announced that their co-developed biosimilar insulin glargine Semglee™ has received marketing authorization approval from the European Commission (EC).

March 27, 2018
·
5 min read
Tetra Bio-Pharma Inc. Announces the Closing of $4,292,000 Non-Brokered Private Placement

Tetra Bio-Pharma Inc. is pleased to announce it has closed its non-brokered private placement of 4,292,000 units at a price of $1.00 per unit for aggregate gross proceeds of $4,292,000.

March 27, 2018
·
1 min read
Deals

After Spurning Pfizer GlaxoSmithKline Cuts $13B Deal with Novartis

GlaxoSmithKline walked away from a potential deal to acquire Pfizer’s consumer health unit four days ago and instead opted to acquire the stake controlled by Novartis. The deal will give GSK 100 percent ownership of the business unit.

March 27, 2018
·
2 min read
·
Alex Keown
FDA

FDA Accepts Bristol-Myers Combo Application

The U.S. Food and Drug Administration (FDA) accepted Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) with Yervoy (ipilimumab) for a type of colorectal cancer.

March 27, 2018
·
2 min read
·
Mark Terry
Biotech Beach

Imprimis Jumps: Secures Patent for Non-Opioid Compound

Imprimis Pharmaceuticals secured a patent that protects its non-opioid sublingual product MKO Melt compound formulation and investors are pleased.

March 27, 2018
·
2 min read
·
Alex Keown
Drug Development

AnaptysBio’s Mid-Stage Peanut Allergy Data Indicates Positive Results

Shares of AnaptysBio were climbing this morning after the company released positive interim data for its experimental peanut allergy treatment. The San Diego-based company said 13 patients or 46 percent of those in its ongoing Phase IIa trial saw increased tolerance to peanuts to 500 mg.

March 27, 2018
·
2 min read
·
Alex Keown
Pharm Country

Novartis Kicks Alcon Spinoff Decision Down the Road to Mid-2019

As Novartis locks in on a $13 billion deal with GlaxoSmithKline (GSK), Novartis chief executive officer Vasant Narasimhan confirms that any decision about spinning off its Alcon eye care business won’t be made until the first half of 2019.

March 27, 2018
·
3 min read
·
Mark Terry
Drug Development

Clot-Busting Stroke Medicine: Mired in Controversy

A common treatment used to break up the clots and prevent brain damage has become mired in controversy. The treatment, called tissue plasminogen activator (TPA), demonstrated in a clinical trial that the medicine could break up those blood clots and prevent brain damage.

March 27, 2018
·
2 min read
·
Alex Keown
Biotech Bay

PDL BioPharma: Buy or Sell

It’s not unusual for a biopharma company, given enough time, to have its ups and downs. But PDL BioPharma’s roller-coaster ride has been more dramatic than most.

March 27, 2018
·
3 min read
·
Mark Terry
Business

After Rova-T Failure, A Look at AbbVie’s Pipeline

Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.

March 27, 2018
·
2 min read
·
Mark Terry